カテゴリー： Global Markets Direct, 医療/バイオ

プロスタグランジンE2受容体EP4サブタイプ治療薬市場：パイプラインレビュー（2019年下半期）

【英語タイトル】Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H2 2019

Global Markets Directが出版した調査資料（GDATA20MY0150）・商品コード：GDATA20MY0150
・発行会社（調査会社）：Global Markets Direct
・発行日：2019年11月25日
・ページ数：64
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：製薬
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,500 ⇒換算￥367,500見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD7,000 ⇒換算￥735,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD10,500 ⇒換算￥1,102,500見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
【レポートの概要】

Prostaglandin E2 Receptor EP4 Subtype – Pipeline Review, H2 2019
Summary

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Prostaglandin E2 Receptor EP4 Subtype – Pipeline Review, H2 2019, outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 1, 6 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology, Women’s Health, Musculoskeletal Disorders and Respiratory which include indications Breast Cancer, Endometriosis, Gastric Cancer, Inflammatory Pain, Liver Cancer, Lung Cancer, Pain, Prostate Cancer, Allergies, Arthritis Pain, Autoimmune Disorders, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Colorectal Cancer, Esophageal Cancer, Familial Adenomatous Polyposis, Gastrointestinal Tract Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Inflammatory Bowel Disease, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Osteoarthritis Pain, Osteogenesis Imperfecta, Osteoporosis, Post-Operative Pain, Rectal Cancer, Rheumatoid Arthritis, Solid Tumor, Triple-Negative Breast Cancer (TNBC) and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
- The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Overview
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Companies Involved in Therapeutics Development
ARTham Therapeutics Inc
AskAt Inc
Eisai Co Ltd
Eli Lilly and Co
GlaxoSmithKline Plc
Kaken Pharmaceutical Co Ltd
Mesentech Inc
NB Health Laboratory Co Ltd
Ono Pharmaceutical Co Ltd
RaQualia Pharma Inc
Rottapharm Biotech Srl
Shanghai Haishi Biopharmaceutical Co Ltd
Sosei Heptares
Tempest Therapeutics Inc
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Drug Profiles
AAT-008 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARTEP – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-6086 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-7046 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
grapiprant – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-726701A – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAG-308 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-4578 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RMX-1002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize EP4 Receptor for Osteoporosis and Osteogenesis Imperfecta – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize EP4 Receptor for Inflammatory Pain – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Prostanoid EP4 Receptor for Inflammatory Bowel Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPST-1495 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Dormant Products
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Discontinued Products
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Product Development Milestones
Featured News & Press Releases
Sep 30, 2019: Adlai Nortye presents encouraging phase 1b study data of AN0025 (an Oral EP4 Antagonist) for locally advanced rectal cancer at ESMO 2019
May 07, 2019: Kyn Therapeutics strengthens leadership team with key appointments
Dec 20, 2018: Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007
Jul 19, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in China
Apr 17, 2018: Japan Patent Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist
Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China
Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China
Dec 18, 2017: Investigational new drug application for EP4 antagonist AAT-007 was approved by the National Food and Drug Administration of the People’s Republic of China
Sep 01, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Korea
Sep 01, 2017: Eisai to Present Abstract on E7046 at ESMO 2017 Congress
Sep 01, 2017: Eisai to Present Abstract on its Oncology Product Candidate E7046 at the ESMO 2017 Congress
Jun 30, 2017: India Patent Office Granted AskAt a Substance Patent of EP4 antagonist(AAT-007)
Apr 25, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Japan
Mar 30, 2017: Treatment of Cancer Use Patent for EP4 antagonist Approved in US
Aug 17, 2016: Treatment of Cancer Use Patent for EP4 antagonist Approved in China
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by ARTham Therapeutics Inc, H2 2019
Pipeline by AskAt Inc, H2 2019
Pipeline by Eisai Co Ltd, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Kaken Pharmaceutical Co Ltd, H2 2019
Pipeline by Mesentech Inc, H2 2019
Pipeline by NB Health Laboratory Co Ltd, H2 2019
Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Pipeline by RaQualia Pharma Inc, H2 2019
Pipeline by Rottapharm Biotech Srl, H2 2019
Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, H2 2019
Pipeline by Sosei Heptares, H2 2019
Pipeline by Tempest Therapeutics Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019

【掲載企業】

ARTham Therapeutics Inc
AskAt Inc
Eisai Co Ltd
Eli Lilly and Co
GlaxoSmithKline Plc
Kaken Pharmaceutical Co Ltd
Mesentech Inc
NB Health Laboratory Co Ltd
Ono Pharmaceutical Co Ltd
RaQualia Pharma Inc
Rottapharm Biotech Srl
Shanghai Haishi Biopharmaceutical Co Ltd
Sosei Heptares
Tempest Therapeutics Inc

★調査レポート[プロスタグランジンE2受容体EP4サブタイプ治療薬市場：パイプラインレビュー（2019年下半期）] (コード：GDATA20MY0150)販売に関する免責事項を必ずご確認ください。
★調査レポート[プロスタグランジンE2受容体EP4サブタイプ治療薬市場：パイプラインレビュー（2019年下半期）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • プロスタグランジンE2受容体EP4サブタイプ(プロスタノイドEP 4受容体／PTGER4)の世界市場：パイプラインレビュー（2018下半期）
    DATA906A326 / Global Markets Direct / 2018年8月14日 / ...Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H2 2018 Summary Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function. Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 11 molecules. Out of...
  • プロスタグランジンD2受容体2治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0149 / Global Markets Direct / 2019年11月25日 / ...Prostaglandin D2 Receptor 2 - Pipeline Review, H2 2019 Summary According to the recently published report 'Prostaglandin D2 Receptor 2 - Pipeline Review, H2 2019'; Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies. Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Prostaglandin D2 (PGD2) receptors are G protein-coupled receptors that...
  • リゾホスファチジン酸受容体1治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0431 / Global Markets Direct / 2019年12月27日 / ...Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2019 Summary According to the recently published report 'Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2019'; Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 7 molecules. Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a group known as EDG receptors. EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, and smooth muscle contraction, inhibition...
  • N-ホルミルペプチド受容体2治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0351 / Global Markets Direct / 2019年12月27日 / ...N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019 Summary According to the recently published report 'N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019'; N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) pipeline Target constitutes close to 8 molecules. N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - N-formyl peptide receptor 2 (FPR2) is a G-protein coupled receptor (GPCR) encoded by the FPR2 gene and is activated...
  • 低血糖治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0172 / Global Markets Direct / 2019年11月29日 / ...Hypoglycemia - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Pipeline Review, H2 2019, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape. Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoglycemia...
  • アリール炭化水素受容体治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0304 / Global Markets Direct / 2019年12月27日 / ...Aryl Hydrocarbon Receptor - Pipeline Review, H2 2019 Summary Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Aryl Hydrocarbon Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Aryl Hydrocarbon...
  • 受容体チロシンプロテインキナーゼERBB4治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0334 / Global Markets Direct / 2019年12月27日 / ...Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H2 2019 Summary According to the recently published report 'Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H2 2019'; Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c...
  • セリアック病治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0099 / Global Markets Direct / 2019年11月25日 / ...Celiac Disease - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H2 2019, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape. Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren’s syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet. Report...
  • 5-ヒドロキシトリプタミン受容体2B治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0403 / Global Markets Direct / 2019年12月27日 / ...5-Hydroxytryptamine Receptor 2B - Pipeline Review, H2 2019 Summary 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report 5-Hydroxytryptamine Receptor 2B - Pipeline Review, H2 2019, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or...
  • 代謝型グルタミン酸受容体1治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0378 / Global Markets Direct / 2019年12月27日 / ...Metabotropic Glutamate Receptor 1 - Pipeline Review, H2 2019 Summary Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) pipeline Target constitutes close to 6 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Metabotropic glutamate...

    • ◆H&Iグローバルリサーチのお客様（例）◆